KURA Stock News & Analysis | Latest Updates

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

(NASDAQ:KURA) Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs)

September 16, 2025Clinical Trials

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

KURA

(NASDAQ:KURA) September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies

September 3, 2025Clinical Trials

Kura Oncology to Participate in Three Upcoming Investor Conferences

KURA

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three investor conferences in September.

August 28, 2025Investor

Kura Oncology And Kyowa Kirin Report Updated Clinical Data From KOMET-007, Phase 1a/1b Trial Of Ziftomenib, In Patients With Newly Diagnosed NPM1-M And KMT2A-R AML

KURA

June 12, 2025

Kura Oncology Grants Stock Options To 5 New Hires Covering 79,200 Shares As Employment Inducement

KURA

June 6, 2025

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $28 Price Target

KURA

June 4, 2025

Kura Oncology And Kyowa Kirin Announce Phase 2 KOMET-001 Trial Results For Once-Daily Oral Menin Inhibitor Ziftomenib In Relapsed/Refractory NPM1-Mutated AML Showing 23% CR/CRh Rate, Durable MRD-Negative Responses Across Key Subgroups, Favorable Safety Wi

KURA

June 2, 2025

Reported Sunday, FDA Grants Priority Review To Kura And Kyowa Kirin's Ziftomenib NDA, Targeting First Menin Inhibitor Approval In NPM1-Mutant AML By November 30

KURA

June 2, 2025

Kura Oncology And Kyowa Kirin Reveal Monotherapy Data for Ziftomenib In Oral Presentation At The 2025 ASCO Annual Meeting

KURA

May 22, 2025

Mizuho Maintains Outperform on Kura Oncology, Lowers Price Target to $30

KURA

May 19, 2025

Kura Oncology And Kyowa Kirin Announce Combination Data For Ziftomenib In Oral Presentation At The 2025 EHA Congress

KURA

May 14, 2025

Barclays Maintains Overweight on Kura Oncology, Lowers Price Target to $11

KURA

May 2, 2025

Kura Oncology Q1 EPS $(0.66), Inline, Sales $14.11M Beat $7.73M Estimate

KURA

May 1, 2025

Uncovering Potential: Kura Oncology's Earnings Preview

KURA

April 30, 2025

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $28 Price Target

KURA

April 29, 2025

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $40 Price Target

KURA

April 28, 2025

Kura Oncology Submits New Drug Application (NDA) To The FDA For ziftomenib For The Treatment Of Acute Myeloid Leukemia (AML)

KURA

April 8, 2025

Kura Oncology to Present Kidney Cancer Drug Combo Data at AACR 2025

KURA

March 26, 2025

Kura Oncology Grants 190,000 Stock Options To Six New Employees As Inducement Awards

KURA

March 7, 2025

UBS Maintains Buy on Kura Oncology, Lowers Price Target to $14

KURA

March 6, 2025

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $40 Price Target

KURA

February 27, 2025

Kura Oncology Q4 GAAP EPS $(0.22) Beats $(0.65) Estimate, Sales $53.88M Beat $8.50M Estimate

KURA

February 26, 2025

Kura Oncology, Kyowa Kirin Enter Global Strategic Collaboration To Develop And Commercialize Ziftomenib; Kura To Receive $330M Upfront Payment And Up To $1.2B In Total Milestone Payments

KURA

November 20, 2024

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target

KURA

November 19, 2024

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target

KURA

November 18, 2024

Cantor Fitzgerald Reiterates Overweight on Kura Oncology

KURA

November 6, 2024

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target

KURA

November 6, 2024

Kura Oncology To Present KOMET-007 Combination Trial Of Ziftomenib Data At ASH Annual Meeting

KURA

November 5, 2024

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target

KURA

May 16, 2024

Kura Oncology Q1 EPS $(0.49) Beats $(0.52) Estimate

KURA

May 4, 2022

KURA News

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

Kura Oncology to Participate in Three Upcoming Investor Conferences

Kura Oncology And Kyowa Kirin Report Updated Clinical Data From KOMET-007, Phase 1a/1b Trial Of Ziftomenib, In Patients With Newly Diagnosed NPM1-M And KMT2A-R AML

Kura Oncology Grants Stock Options To 5 New Hires Covering 79,200 Shares As Employment Inducement

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $28 Price Target

Kura Oncology And Kyowa Kirin Announce Phase 2 KOMET-001 Trial Results For Once-Daily Oral Menin Inhibitor Ziftomenib In Relapsed/Refractory NPM1-Mutated AML Showing 23% CR/CRh Rate, Durable MRD-Negative Responses Across Key Subgroups, Favorable Safety Wi

Reported Sunday, FDA Grants Priority Review To Kura And Kyowa Kirin's Ziftomenib NDA, Targeting First Menin Inhibitor Approval In NPM1-Mutant AML By November 30

Kura Oncology And Kyowa Kirin Reveal Monotherapy Data for Ziftomenib In Oral Presentation At The 2025 ASCO Annual Meeting

Mizuho Maintains Outperform on Kura Oncology, Lowers Price Target to $30

Kura Oncology And Kyowa Kirin Announce Combination Data For Ziftomenib In Oral Presentation At The 2025 EHA Congress

Barclays Maintains Overweight on Kura Oncology, Lowers Price Target to $11

Kura Oncology Q1 EPS $(0.66), Inline, Sales $14.11M Beat $7.73M Estimate

Uncovering Potential: Kura Oncology's Earnings Preview

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $28 Price Target

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $40 Price Target

Kura Oncology Submits New Drug Application (NDA) To The FDA For ziftomenib For The Treatment Of Acute Myeloid Leukemia (AML)

Kura Oncology to Present Kidney Cancer Drug Combo Data at AACR 2025

Kura Oncology Grants 190,000 Stock Options To Six New Employees As Inducement Awards

UBS Maintains Buy on Kura Oncology, Lowers Price Target to $14

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $40 Price Target

Kura Oncology Q4 GAAP EPS $(0.22) Beats $(0.65) Estimate, Sales $53.88M Beat $8.50M Estimate

Kura Oncology, Kyowa Kirin Enter Global Strategic Collaboration To Develop And Commercialize Ziftomenib; Kura To Receive $330M Upfront Payment And Up To $1.2B In Total Milestone Payments

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target

Cantor Fitzgerald Reiterates Overweight on Kura Oncology

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target

Kura Oncology To Present KOMET-007 Combination Trial Of Ziftomenib Data At ASH Annual Meeting

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target

Kura Oncology Q1 EPS $(0.49) Beats $(0.52) Estimate